Clinical trials report

Dormandy JA, Charbonnel B, Eckland DJ, et al.; PROactive investigators: Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PRO-spective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005, 366:1279–1289. Goldberg RB, Kendall DM, Deeg MA, et al.: A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005, 28:1547–1554. Iida KT, Kawakami Y, Suzuki M, et al.: Effect of thiazolidinediones and metformin on LDL oxidation and aortic endothelium relaxation in diabetic GK rats. Am J Physiol Endocrinol Metab 2003, 284:E1125–1130. Gerstein HC, Yusuf S, Bosch J, et al.; DREAM (Diabetes Reduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators: Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomized controlled trial. Lancet 2006, 368:1096–1105. Scott R, Best J, Forder P, et al.; FIELD study investigators: Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study, a randomized, placebo-controlled trial: baseline characteristics and short-term effects of fenofibrate. Cardiovasc Diabetol 2005, 4:13. Tenenbaum A, Motro M, Fisman EZ, et al.: Bezafibrate for the secondary prevention of myocardial in farction in patients with metabolic syndrome. Arch Intern Med 2005, 165:1154–1160. Wood D, Wray R, Poulter N, et al.: Joint British Societies guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005, 91(Suppl):v1-v52. Rubins HB, Robins SJ, Collins D, et al.: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol: Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trail Study Group. N Engl J Med 1999, 341:410–418. Knopp RH, d’Emden M, Smilde JG, Pocock SJ, on behalf of the ASPEN Study Group: Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes. Diabetes Care 2006, 29:1478–1485. Harris SB, Ekoe JM, Zdamowicz Y, Webster-Bogaert S: Glycemic control and morbidity in the Canadian primary care setting (results of the diabetes in Canada evaluation study). Diabetes Res Clin Pract 2005, 70:90–97. Colhoun HM, Betteridge DJ, Durrington PN, et al.; CARDS investigators: Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial [see comment]. Lancet 2004, 364:685–696. Gaede P, Vedel P, Larson N, et al.: Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003, 348:383–393.